Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06177522
Other study ID # DZQH-KYLL-23-26
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date December 2023
Est. completion date December 2026

Study information

Verified date December 2023
Source Jinling Hospital, China
Contact Xinbo Wang, MD
Phone 13505172912
Email wxinbo2008@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Clinical Study on the Safety and Efficacy of the efficacy and safety of adbelizumab combined with chemotherapy for neoadjuvant treatment of resectable pancreatic cancer


Description:

The goal of this clinical trial is to observe and evaluate the efficacy and safety of adbelizumab combined with chemotherapy for neoadjuvant treatment of resectable pancreatic cancer.The main questions it aims to answer are: To investigate the feasibility of immunotherapy combined with chemotherapy in the neoadjuvant therapy of pancreatic cancer. To explore more effective neoadjuvant therapies for pancreatic cancer. Participants will receive 2 cycles of aldebelizumab in combination with albumin-bound paclitaxel and gemcitabine in the neoadjuvant phase, followed by surgery.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date December 2026
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility inclusion criteria 1. Age 18-80 years old, gender unlimited; 2. Patients with resectable pancreatic adenocarcinoma confirmed by histopathology or cytology (CA19-9 > 500 U/ml); 3. No previous systemic treatment for pancreatic cancer; 4. Measurable lesions defined by RECIST standard v1.1 (according to Recist 1.1 standard, the CT scan diameter of tumor lesions is =10 mm, and the scan layer thickness is not more than 5 mm); 5. ECOG score: 0 ~ 1; 6. Having adequate organ and bone marrow function, as defined below: Hemoglobin =9.0 g/dL neutrophil absolute count =1.5×109/L Platelet count =100×109/L INR=1.5 Total bilirubin (TBL) =1.5× upper limit of normal (ULN) AST and ALT=2.5×ULN Serum albumin =3.0 g/dL serum creatinine =1.5×ULN or measured creatinine clearance > 60 mL/min or creatinine clearance > 60 mL/min calculated according to the Cockcroft-Gault formula (using actual body weight) : Men: creatinine clearance =(weight x (140- age))/(72 x serum creatinine) Women: Creatinine clearance =(body weight x (140-age))/(72 x serum creatinine)x 0.85, where CL=mL/min; Serum creatinine =mg/dL; 7. Patients with active HBV infection should receive antiviral therapy for more than 2 weeks according to local antiviral treatment guidelines before enrollment, and should continue treatment for 6 months after study drug therapy; 8. A negative hepatitis C virus (HCV) antibody test at screening, or a positive HCV antibody test at screening and a subsequent negative HCV RNA test; 9. Expected survival =12 weeks; 10. The investigator determined that the patient could receive adabilimab therapy; 11. Subjects voluntarily participate in this study and sign informed consent. exclusion criteria 1. Concurrent with other uncured malignant tumors; 2. Subjects who have previously used PD-1/PD-L1 antibodies; 3. Subjects who can be surgically resected or treated with radical radiation; 4. Subjects with a history of bleeding and any bleeding event with a severity rating of 3 or above on CTCAE4.0 within 4 weeks prior to screening; 5. Urine routine indicated urinary protein =++ and confirmed 24-hour urinary protein quantity > 1.0g; 6. Subjects with poorly controlled hypertension; 7. Subjects who have experienced serious infection within 4 weeks prior to the first dose, including but not limited to infection complications requiring hospitalization, bacteremia, severe pneumonia, etc. Subjects who developed a severe active infection requiring intravenous antibiotic treatment during screening; 8. Subjects requiring systemic treatment with corticosteroids (>10 mg/ day of prednisone or equivalent) or other immunosuppressants within 14 days prior to initial medication. In the absence of active autoimmune disease, inhaled or topical corticosteroids are permitted, as well as adrenal hormone replacement therapy at doses > 10 mg/ day of prednisone efficacy; 9. History of chronic autoimmune diseases, such as systemic lupus erythematosus, ulcerative enteritis, Crohn's disease and other inflammatory bowel diseases; Except for hypothyroidism that requires only hormone replacement therapy and skin diseases that do not require systemic treatment (such as vitiligo, psoriasis or alopecia); 10. Subjects with grade II or above myocardial ischemia or myocardial infarction, poorly controlled arrhythmias (including QTc interval =450 ms for men and =470 ms for women). Subjects with NYHA standard ? ~ ? cardiac insufficiency or LVEF (left ventricular ejection fraction) < 50% were excluded; 11. Subjects who are preparing for or have previously received tissue/organ transplants; 12. Subjects who have received or will receive live vaccine within 30 days prior to the first dose; 13. Subjects with a history of difficult to control mental illness or severe intellectual or cognitive impairment; 14. Subjects with active hepatitis: hepatitis B virus surface antigen (HBV) positive with HBV DNA= 2000 IU/mL, hepatitis C virus antibody (HCV Ab) positive, HCV RNA positive, abnormal liver function, combined with hepatitis B and hepatitis C co-infection; 15. Subjects with uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage; 16. Allergic to the experimental drug; 17. Women who are pregnant, breastfeeding or have given birth but refuse to use contraceptives; 18. Other conditions deemed unsuitable for inclusion by the researchers.

Study Design


Intervention

Drug:
Adbelimumab
1200mg,i.v. , q3w
albumin-bound paclitaxel
125 mg/m2, i.v.,d1,d8, q3w
Gemcitabine
1.0 g/m2, i.v.,d1, d8, q3w

Locations

Country Name City State
China Wang Sizhen Nanjing Jiangsu

Sponsors (2)

Lead Sponsor Collaborator
Jinling Hospital, China Jiangsu Hengrui Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary R0 removal rate To observe and evaluate the efficacy and safety of adbelizumab combined with chemotherapy for neoadjuvant treatment of resectable pancreatic cancer one year
Primary pCR rate To observe and evaluate the efficacy and safety of adbelizumab combined with chemotherapy for neoadjuvant treatment of resectable pancreatic cancer one year
See also
  Status Clinical Trial Phase
Completed NCT05305001 - Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT05497531 - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers N/A
Recruiting NCT06054984 - TCR-T Cells in the Treatment of Advanced Pancreatic Cancer Early Phase 1
Recruiting NCT04927780 - Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer Phase 3
Recruiting NCT05919537 - Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation Phase 1
Terminated NCT03140670 - Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy Phase 2
Terminated NCT00529113 - Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer Phase 1
Recruiting NCT05168527 - The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Recruiting NCT05391126 - GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care N/A
Terminated NCT03300921 - A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer Phase 1
Completed NCT03153410 - Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas Early Phase 1
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Recruiting NCT05679583 - Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer Phase 2
Recruiting NCT04183478 - The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer Phase 2/Phase 3
Terminated NCT03600623 - Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer Early Phase 1
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A
Recruiting NCT05351983 - Patient-derived Organoids Drug Screen in Pancreatic Cancer N/A
Completed NCT04290364 - Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study